Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Swetnam, James ^a   Shmelkov, Evgeny ^a   Zolla Pazner, Susan ^a,b   Cardozo, Timothy ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; EPITOPE; RECOMBINANT VACCINE;

AMINO ACID SEQUENCE; ARTICLE; GENE STRUCTURE; GENE TARGETING; GENETIC CONSERVATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PROTEIN DOMAIN; STRAIN DIFFERENCE; VIRUS GENE; VIRUS NEUTRALIZATION; VIRUS STRAIN; BIOLOGY; CHEMISTRY; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; METABOLISM; METHODOLOGY; PROTEIN CONFORMATION; PROTEIN MOTIF; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID MOTIFS; ANTIBODIES, MONOCLONAL; COMPUTATIONAL BIOLOGY; EPITOPE MAPPING; EPITOPES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGENETICS; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; VACCINES, SYNTHETIC;

EID: 78650833474     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015994     Document Type: Article

References (50)

1. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, et al. (1990) Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. Aids 4: 107-112.
2. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, et al. (1992) Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355: 728-730.
3. Andrus L, Prince AM, Bernal I, McCormack P, Lee DH, et al. (1998) Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J Infect Dis 177: 889-897.
4. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, et al. (1997) Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 3: 1389-1393.
5. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, et al. (2004) Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 189: 2167-2173.
6. Ruprecht RM (2009) Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Methods Mol Biol 525: 559-566.
7. Wang CY, Sawyer LS, Murthy KK, Fang X, Walfield AM, et al. (1999) Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc Natl Acad Sci U S A 96: 10367-10372.
8. Safrit JT, Fung MS, Andrews CA, Braun DG, Sun WN, et al. (1993) hu-PBLSCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. Aids 7: 15-21.
9. Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, et al. (2005) Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 79: 780-790.
10. Vogel T, Kurth R, Norley S (1994) The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J Immunol 153: 1895-1904.
11. Zolla-Pazner S (2005) Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 14: 69-72.
12. Israel ZR, Gorny MK, Palmer C, McKeating JA, Zolla-Pazner S (1997) Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals. Aids 11: 128-130.
13. McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, et al. (1993) Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol 67: 4932-4944.
14. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals. Nature 458: 636-640.
15. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature 455: 613-619.
16. Zolla-Pazner S (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4: 199-210.
17. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
18. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM (1997) Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 71: 3734-3741.
19. Gorny MK, Van Cott TC, Hioe C, Israel ZR, Michael NL, et al. (1997) Human monoclonal antibodies to the V3 loop of HIV-1 with intra-and interclade crossreactivity. J Immunol 159: 5114-5122.
20. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-.2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
21. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905.
22. Pinter A, Honnen WJ, Racho ME, Tilley SA (1993) A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. AIDS Res Hum Retroviruses 9: 985-996.
23. Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, et al. (1991) Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 65: 489-493.
24. Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, et al. (2004) The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 78: 2394-2404.
25. Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA (2006) Crystal Structures of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity. J Virol 80: 6093-6105.
26. Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769.
27. Zolla-Pazner S, Cohen S, Pinter A, Krachmarov C, Wrin T, et al. (2009) Crossclade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 392: 82-93.
28. Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, et al. (2004) The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res Hum Retroviruses 20: 1254-1258.
29. Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, et al. (2002) Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 76: 9035-9045.
30. Cardozo T, Swetnam J, Pinter A, Krachmarov C, Nadas A, et al. (2009) Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. AIDS Res Hum Retroviruses 25: 441-450.
31. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, et al. (2010) Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol 17: 955-961.
32. Burke V, Williams C, Sukumaran M, Kim SS, Li H, et al. (2009) Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure 17: 1538-1546.
33. Hemelaar J, Gouws E, Ghys PD, Osmanov S (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-23.
34. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J (2002) Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 29: 184-190.
35. Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, et al. (2010) Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One 5: e10254.
36. Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, et al. (2007) Type-Specific Epitopes Targeted by Monoclonal Antibodies with Exceptionally Potent Neutralizing Activities for Selected Strains of Human Immunodeficiency Virus Type 1 Map to a Common Region of the V2 Domain of gp120 and Differ Only at Single Positions from the Clade B Consensus Sequence. J Virol 81: 1424-1432.
37. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
38. Sattentau Q, Moore J (1995) Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 182: 185-196.
39. Cavacini LA, Duval M, Robinson Ja, Posner MR (2002) Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. [Miscellaneous Article]. AIDS December 16: 2409-2417.
40. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, et al. (2004) The V1/ V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78: 5205-5215.
41. Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, et al. (2002) Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades. J Virol 76: 9035-9045.
42. Conley AJ, Gorny MK, Kessler 2nd JA, Boots LJ, Ossorio-Castro M, et al. (1994) Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 68: 6994-7000.
43. Krachmarov CP, Kayman SC, Honnen WJ, Trochev O, Pinter A (2001) V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17: 1737-1748.
44. Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, et al. (2004) The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope. J Virol 78: 2394-2404.
45. Wu X, Sambor A, Nason MC, Yang Z-Y, Wu L, et al. (2008) Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. Virology 380: 285-295.
46. Mbah HA, Burda S, Gorny MK, Williams C, Revesz K, et al. (2001) Effect of Soluble CD4 on Exposure of Epitopes on Primary, Intact, Native Human Immunodeficiency Virus Type 1 Virions of Different Genetic Clades. J Virol 75: 7785-7788.
47. Visciano ML, Tuen M, Gorny MK, Hioe CE (2008) In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology 372: 409-420.
48. Vijh-Warrier S, Pinter A, Honnen W, Tilley S (1996) Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J Virol 70: 4466-4473.
49. Zolla-Pazner S, Cohen S, Pinter A, Krachmarov C, Wrin T, et al. (2009) Crossclade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology.
50. Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, et al. (2008) Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372: 233-246.